Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor)
Published Date: 1/10/2025
Notice
Summary
The FDA just gave the green light to ALYFTREK, a new medicine for rare childhood diseases, using a special priority review voucher that speeds up approval. This means kids with rare conditions can get access to this treatment faster, and drug makers get rewarded for developing these important medicines. The approval happened on December 20, 2024, marking a big win for patients and innovators alike!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Approval of ALYFTREK
The FDA approved ALYFTREK (vanzacaftor, tezacaftor, and deutivacaftor) tablets on December 20, 2024 as a rare pediatric disease product under the Rare Pediatric Disease Priority Review Voucher program. If you are a parent or guardian of a child for whom ALYFTREK is indicated, this approval is the official FDA authorization of that product.
Voucher Awarding to Drug Sponsors
Under section 529 of the Federal Food, Drug, and Cosmetic Act, FDA awards Rare Pediatric Disease Priority Review Vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. The notice confirms that a voucher was redeemed in the approval of ALYFTREK.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-13176 — World Trade Center Health Program; Petitions 024, 042, 046, 047, 051, 056, 058, and 067-Ischemic Heart Disease; Finding of Insufficient Evidence
The World Trade Center Health Program reviewed eight petitions asking to add ischemic heart disease to the list of covered health conditions but found there isn’t enough proof to do so right now. This means people affected by 9/11 won’t see changes to their benefits for this heart condition at this time. The decision was made official on June 30, 2026, with no new costs or coverage changes coming soon.
2026-13128 — Certain Photovoltaic Trunk Bus Cable Assemblies and Components Thereof; Notice of Final Determination Finding a Violation of Section 337; Issuance of a Limited Exclusion Order; Termination of Investigation
The U.S. International Trade Commission found that Voltage, LLC and its Chinese partner broke patent rules by selling certain solar panel cable parts in the U.S. To stop this, the Commission issued a limited ban on these products and requires a 100% cash bond on imports during review. This means Voltage’s infringing products can’t enter the U.S. market, protecting Shoals Technologies and encouraging fair competition.
2026-13098 — Crewmember Access Point
Starting January 1, 2027, aircraft operators who want their crewmembers to skip long security lines at certain U.S. airports will pay a $19 yearly fee per employee to join the Crewmember Access Point program. This change affects airlines like Delta, American, and FedEx, making it easier and faster for their crews to get through security while helping TSA keep things safe. Operators will get clear instructions on how to sign up and pay the fee.
2026-13112 — Self-Regulatory Organizations; Municipal Securities Rulemaking Board; Notice of Filing and Immediate Effectiveness of a Proposed Rule Change Consisting of Amendments to MSRB Rule G-28, on Transactions With Employees and Partners of Other Municipal Securities Professionals, To Harmonize and Better Align With FINRA Rule 3210, on Accounts at Other Broker-Dealers and Financial Institutions
The MSRB is updating Rule G-28 to match FINRA’s Rule 3210, making rules clearer for brokers and dealers about accounts they or their partners have at other firms. Now, employees must get written permission from their employer before opening or having interest in these accounts, and they must notify the other firms about their employer ties. These changes take effect immediately and help keep things fair and transparent in municipal securities trading.
2026-13134 — Submission for Office of Management and Budget Review; Adoption and Foster Care Analysis and Reporting System (AFCARS)
The government is updating the Adoption and Foster Care Analysis and Reporting System (AFCARS) to include 62 new data points, mainly about protections for Native children. This change affects state child welfare agencies, making their reporting a bit more detailed and time-consuming. Comments on this update are open until July 30, 2026, helping shape how the system supports kids in foster care and adoption.
2026-13110 — Name of Information Collection: NASA Astronaut Candidate Selection Qualifications Inquiry
NASA is updating how it collects info about astronaut applicants by asking their bosses, co-workers, and references for feedback. This helps NASA pick the best space explorers while cutting down on paperwork. If you’re involved, get ready to share your thoughts by July 30, 2026—no extra costs, just a smoother astronaut selection process!
Previous / Next Documents
Previous: 2025-00340 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; CRENESSITY (crinecerfont)
The FDA just gave a special priority review voucher to Neurocrine Biosciences for their rare pediatric disease drug, CRENESSITY (crinecerfont), approved in December 2024. This voucher speeds up future drug reviews, helping get important medicines to kids faster. It’s a big win for patients with rare diseases and could save time and money in drug development.
Next: 2025-00342 — National Antimicrobial Resistance Monitoring System 2026-2030 Strategic Plan; Request for Comments
The FDA is updating its plan to track and fight antibiotic resistance from 2026 to 2030 and wants your ideas by March 26, 2025. This affects anyone involved in food safety, healthcare, and public health because stronger monitoring means better protection against tough germs. The new plan will guide smarter actions and investments to keep antibiotics working well for everyone.